The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases
This guidance provides a data‐supported approach to the diagnostic, therapeutic, and
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document is …
preventive aspects of nonalcoholic fatty liver disease (NAFLD) care. A “Guidance” document is …
[PDF][PDF] The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American …
…, EM Brunt, K Cusi, M Charlton, AJ Sanyal - …, 2012 - Wiley Online Library
… Arun Sanyal, MD has served as an ad hoc advisor to Roche, Takeda, Merck, Astella, Sanofi,
Exhalenz, and Immuron. He serves as the global PI for trials for Exhalenz and Immuron. …
Exhalenz, and Immuron. He serves as the global PI for trials for Exhalenz and Immuron. …
Mechanisms of NAFLD development and therapeutic strategies
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD), paralleling
a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver …
a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum of liver …
[HTML][HTML] The accessible chromatin landscape of the human genome
…, AP Reynolds, V Roach, A Safi, ME Sanchez, A Sanyal… - Nature, 2012 - nature.com
DNase I hypersensitive sites (DHSs) are markers of regulatory DNA and have underpinned
the discovery of all classes of cis-regulatory elements including enhancers, promoters, …
the discovery of all classes of cis-regulatory elements including enhancers, promoters, …
[HTML][HTML] Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
Background Nonalcoholic steatohepatitis is a common liver disease that can progress to
cirrhosis. Currently, there is no established treatment for this disease. Methods We randomly …
cirrhosis. Currently, there is no established treatment for this disease. Methods We randomly …
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
AJ Sanyal, C Campbell–Sargent, F Mirshahi, WB Rizzo… - Gastroenterology, 2001 - Elsevier
Background and Aims: The pathogenesis of nonalcoholic steatohepatitis (NASH) is unknown.
We tested the hypothesis that NASH is associated with 2 defects: (1) peripheral insulin …
We tested the hypothesis that NASH is associated with 2 defects: (1) peripheral insulin …
[PDF][PDF] Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH)
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …
are highly prevalent in the United States, where they are a growing cause of cirrhosis and …
[HTML][HTML] Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis …
Background & Aims Elafibranor is an agonist of the peroxisome proliferator−activated
receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves insulin …
receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves insulin …
[HTML][HTML] Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis
(NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. …
(NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. …
[HTML][HTML] Prospective study of outcomes in adults with nonalcoholic fatty liver disease
Background The prognoses with respect to mortality and hepatic and nonhepatic outcomes
across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well …
across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well …